(Q54667186)

2 June 2018

title

MRI with magnetic nanoparticles monitors downstream anti-angiogenic effects of mTOR inhibition. (English)

1 reference

2 June 2018

main subject

magnetite nanoparticle

0 references

nanoparticle

0 references

angiogenesis inhibitor

1 reference

inferred from title

magnetic nanoparticle

1 reference

5

Ralph Weissleder

1 reference

2 June 2018

author name string

Alexander R Guimaraes

1

1 reference

2 June 2018

Robert Ross

2

1 reference

2 June 2018

Jose L Figuereido

3

1 reference

2 June 2018

Peter Waterman

4

1 reference

2 June 2018

publication date

1 April 2011

1 reference

2 June 2018

Molecular Imaging and Biology

published in

1 reference

2 June 2018

volume

13

1 reference

2 June 2018

issue

2

1 reference

2 June 2018

page(s)

314-320

1 reference

2 June 2018

Sorafenib in advanced clear-cell renal-cell carcinoma

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0357-2

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0357-2

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0357-2

In vivo assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0357-2

Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0357-2

Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0357-2

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0357-2

Anti-angiogenic targets in the treatment of advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0357-2

Targeting angiogenesis in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0357-2

mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0357-2

All roads lead to mTOR: integrating inflammation and tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0357-2

RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0357-2

Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0357-2

Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0357-2

Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0357-2

Steady-state blood volume measurements in experimental tumors with different angiogenic burdens a study in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0357-2

Magnetic resonance imaging monitors physiological changes with antihedgehog therapy in pancreatic adenocarcinoma xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0357-2

MR contrast due to intravascular magnetic susceptibility perturbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0357-2

NMR imaging of changes in vascular morphology due to tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0357-2

Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-010-0357-2

In vivo assessment of RAS-dependent maintenance of tumor angiogenesis by real-time magnetic resonance imaging

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20559742

12 December 2020

inferred from PubMed ID database lookup

Antiangiogenic tumor treatment: early noninvasive monitoring with USPIO-enhanced MR imaging in mice

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20559742

12 December 2020

inferred from PubMed ID database lookup

To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20559742

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1007/S11307-010-0357-2

1 reference

2 June 2018

1 reference

2 June 2018